2013 - ISBTS 2013 Symposium

This page contains exclusive content for the member of the following sections: TTS, IXA, ITA. Log in to view.

Oral Communications 2

8.222 - Soluble HLA-G as tolerogenic immunomodulant in experimental small bowel transplantation

Presenter: Martin, von Websky, , Germany
Authors: Martin von Websky¹, Koji Kitamura¹, Thomas Pech¹, Isis Ludwig-Portugall², Joel LeMaoult³, Kareem Abu-Elmagd⁴, Joerg Kalff¹, Nico Schaefer¹

Soluble HLA-G as tolerogenic immunomodulant in experimental small bowel transplantation

Martin von Websky¹, Koji Kitamura¹, Thomas Pech¹, Isis Ludwig-Portugall², Joel LeMaoult³, Kareem Abu-Elmagd⁴, Joerg Kalff¹, Nico Schaefer¹

¹Visceral Surgery, University Hospital of Bonn, Bonn, Germany; ²experimental Immunology, University of Bonn, Bonn, Germany; ³Service de recherches en hÃ©mato-immunologie, Hopital Saint-Louis, Paris, France; ⁴Transplant Institute, Cleveland Clinic, Cleveland, OH, United States

Background:

HLA-G is a non-classical member of the HLA family and has been implicated with a central role in fetomaternal tolerance. It partakes in the protection of the fetus (a semi-allogenic allograft) from the mother’s immune system via downregulating adaptive (T cell) and innate (NK cell) immunity. Promising studies have shown immunosuppressive effects of HLA-G in transplantation and allogenic skin allografts were accepted in mice using HLA-G as tolerogenic immunomodulant^[1]. In this study, soluble HLA-G dimers are evaluated in experimental intestinal transplantation – a solid organ especially prone to acute and chronic rejection.

Methods:

Allogenic intestinal transplantation (ITX) was performed in rats (BN ->Lew). HLA-G was coated on polystyrene beads and administered intraperitoneally 24h prior to and upon completion of the transplant. Animals were harvested at 4 and 7 days posttransplant and acute rejection (ACR), as well as effects on T-cell adaptive immune responses were assessed by flow cytometry, histology, graft contractility and qPCR.

Results:

HLA-G treatment was observed to significantly protect grafts from histologically proven ACR as assessed by two independent reviewers using the Wu rejection score. While no difference was observed in CD4⁺ T-cells isolated from graft draining lymphnodes, effector CD8⁺ cells were found to be significantly reduced after HLA-G treatment at 7 days post allogenic ITX. Furthermore, CD4⁺/CD25⁺/FoxP3⁺ T_reg cells appeared to be induced by HLA-G treatment. Graft infiltration with myeloperoxidase positive cells was significantly reduced after HLA treatment at 7 days post ITX concomitantly to ameliorated graft contractility. qPCR showed a significant reduction in ACR-related cytokine expression (TNF α, IL 10, IFN γ) after HLA-G treatment at 4 and 7 days post ITX.

Conclusion:

Soluble HLA-G dimers exhibit tolerogenic properties in this model of experimental intestinal transplantation. The protective effect may be mediated via inhibition of the effector CD8⁺population either directly or by induction of specific T_reg populations. Further studies examining the efficacy and mechanism of HLA-G as tolerogenic immunomodulant in intestinal transplantation are warranted.

By viewing the material on this site you understand and accept that:

The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
The material is solely for educational purposes for qualified health care professionals.
The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
The information cannot be used as a substitute for professional care.
The information does not represent a standard of care.
No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada

Member Login